These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 30694564)
1. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344. Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428 [TBL] [Abstract][Full Text] [Related]
3. SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules. Wang F; Zheng L; Yi Y; Yang Z; Qiu Q; Wang X; Yan W; Bai P; Yang J; Li D; Pei H; Niu T; Ye H; Nie C; Hu Y; Yang S; Wei Y; Chen L Mol Cancer Ther; 2018 Apr; 17(4):763-775. PubMed ID: 29610282 [TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway. Huang Z; Xia Y; Hu K; Zeng S; Wu L; Liu S; Zhi C; Lai M; Chen D; Xie L; Yuan Z J Neurochem; 2020 Jan; 152(2):221-234. PubMed ID: 31390677 [TBL] [Abstract][Full Text] [Related]
6. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303 [TBL] [Abstract][Full Text] [Related]
7. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma. Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933 [TBL] [Abstract][Full Text] [Related]
8. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation. Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806 [TBL] [Abstract][Full Text] [Related]
9. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953 [TBL] [Abstract][Full Text] [Related]
10. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma. Wang F; Zhong BW; Zhao ZR J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566 [TBL] [Abstract][Full Text] [Related]
11. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811 [TBL] [Abstract][Full Text] [Related]
12. A novel class of anthraquinone-based HDAC6 inhibitors. Song Y; Lim J; Seo YH Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327 [TBL] [Abstract][Full Text] [Related]
13. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Meng Z; Jia LF; Gan YH Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303 [TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation. Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Auzmendi-Iriarte J; Saenz-Antoñanzas A; Mikelez-Alonso I; Carrasco-Garcia E; Tellaetxe-Abete M; Lawrie CH; Sampron N; Cortajarena AL; Matheu A Cell Death Dis; 2020 Jun; 11(6):417. PubMed ID: 32488056 [TBL] [Abstract][Full Text] [Related]
16. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502 [TBL] [Abstract][Full Text] [Related]
18. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness. Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427 [TBL] [Abstract][Full Text] [Related]
19. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors. Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697 [TBL] [Abstract][Full Text] [Related]
20. Structure, Functions and Selective Inhibitors of HDAC6. Liang T; Fang H Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]